Also trades as: 1672.HK (HKSE) · $vol 3M
ASCLF OTC
Ascletis Pharma Inc.
1W: -13.3%
1M: -18.8%
3M: -30.7%
YTD: -30.2%
1Y: -14.8%
3Y: +73.3%
5Y: +173.7%
$1.04
-0.08 (-7.14%)
Weekly Expected Move ±10.3%
$1
$1
$1
$1
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$1M
-97.7% ▼
5Y CAGR: -62.5%
Gross Profit
$735K
-97.2% ▼
5Y CAGR: -64.2%
Operating Income
-$295M
+1.6% ▲
Net Income
-$301M
-108.0% ▼
EPS (Diluted)
$-0.30
-130.8% ▼
EBITDA
-$390M
-209.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $35M | $77M | $54M | $57M | $1M |
| YoY Growth | -79.8% | +119.6% | -29.6% | +4.6% | -97.7% |
| Cost of Revenue | $58M | $38M | $79M | $31M | $548K |
| Gross Profit | -$23M | $39M | -$25M | $26M | $735K |
| Gross Margin | -67.1% | 51.0% | -45.6% | 45.9% | 57.3% |
| R&D Expenses | $109M | $213M | $267M | $217M | $302M |
| SG&A Expenses | $48M | $37M | $32M | $63M | $102M |
| Operating Expenses | $129M | $264M | $319M | $326M | $296M |
| Operating Income | -$217M | -$225M | -$344M | -$300M | -$295M |
| Operating Margin | -620.3% | -292.6% | -635.9% | -530.4% | -23025.6% |
| Interest Expense | $135K | $125K | $157K | $144K | $0 |
| Income Before Tax | -$209M | -$199M | -$315M | -$145M | -$301M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$209M | -$199M | -$315M | -$145M | -$301M |
| Net Margin | -597.8% | -258.9% | -582.1% | -255.7% | -23455.7% |
| EPS (Diluted) | $-0.20 | $-0.18 | $-0.29 | $-0.13 | $-0.30 |
| EBITDA | -$182M | -$169M | -$284M | -$126M | -$390M |
| Shares Outstanding | 1.04B | 1.10B | 1.09B | 1.07B | 1.00B |